Hemophilia B

Disease State Hub

FDA Alerts

Hematology

New Treatment Option for Hemophilia Approved

06/01/2017

The US Food and Drug Administration recently approved a new treatment option for patients with hemophilia B.

06/01/2017

Research Summaries

FAQ

FAQ

Hemophilia B in Primary Care: 5 Key Questions About Recognition, Diagnosis, and Management

09/15/2026

Primary care physicians can help identify previously unrecognized hemophilia B, respond appropriately to bleeding and procedural risks, reinforce hematology-directed treatment plans, and support patients...

09/15/2026

Research Summary

Research Summary

5-Year HOPE-B Data Support Durable Hemophilia B Gene Therapy

07/27/2026

Ashton L. Stahl

Final phase 3 results assessed 5-year efficacy and safety of etranacogene dezaparvovec in adults with hemophilia B.

07/27/2026

Research Summary

Research Summary

Hemophilia B Gene Therapy Maintains FIX Activity, Low Bleeding Rates at 6 Years

06/15/2026

Anthony Calabro, MA

In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.

06/15/2026

Bleeding Disorders

Bleeding Disorders

FDA Approves First Gene Therapy for Hemophilia B

11/28/2022

The first of its kind gene therapy treatment has been approved by the FDA for adults with Hemophilia B.

11/28/2022

Hematology

New Treatment Option for Hemophilia Approved

06/01/2017

The US Food and Drug Administration recently approved a new treatment option for patients with hemophilia B.

06/01/2017

September 2026

Current Issue

September 2026